Analysis Group Researchers’ Poster Lauded at Annual Meeting of Psychopharmacologic Professionals
July 06, 2012
The poster "The Impact of Study Design in Comparative Effectiveness Research in Schizophrenia," coauthored by several consultants from Analysis Group’s Health Care Consulting practice and researchers from the University of Pennsylvania and Otsuka America Pharmaceutical, Inc., received a best poster ribbon at the annual meeting of the New Clinical Drug Evaluation Unit (NCDEU).
In the poster, the research team, which included Manager Noam Kirson, Vice President Sander Yermakov, Associate Wayne Huang, and Managing Principal Paul Greenberg, explore the question of how research design can affect estimates of the comparative effectiveness of oral and depot formulations of antipsychotic drugs.
The researchers performed a meta-analysis of 13 published studies (five randomized controlled trials, eight observational) that compared depot and oral formulations of antipsychotic drugs. They found that depot antipsychotics display increasing effectiveness compared with oral formulations as study design shifts from randomized controlled trials toward real-world clinical settings, suggesting that differences in control over compliance exerted in the respective designs could be a contributing factor.
The NCDEU meeting, cosponsored by the American Society of Clinical Psychopharmacology, is focused on the latest developments in psychopharmacologic clinical research and related methodology.
View the poster